New Mechanisms, New Medications for Psychosis

This presentation reviews the evidence showing antipsychotic properties can be conferred by agents that do not bind to D2 receptors; the preclinical and clinical evidence underlying the antipsychotic mechanisms underlying 5-HT2A antagonism, muscarinic M4 agonism, and TAAR1 agonism; and how TAAR1 agonists modulate activity at presynaptic and postsynaptic D2 receptors via a G-protein independent pathway (Akt/β-arrestin2/glycogen synthase kinase 3β).
Jonathan M. Meyer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 3.04 MB
Released: March 22, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

 
Independent Educational Activity

Related Content

Slides from a presentation that educates clinicians on the identification and management of tardive dyskinesia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on antipsychotic treatment of schizophrenia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing major depression.

Manish Jha, MD Greg W. Mattingly, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing bipolar depression and mixed presentations

Charles DeBattista, MD Roger McIntyre, MD, FRCPC Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings